-

Thermo Fisher Scientific demonstrates commitment to transplant patients and collaboration at ASHI 2022

Multiple abstracts, three sponsored sessions and patient advocacy campaign debut top company contribution to conference that draws attendees from around the world

LAS VEGAS--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will demonstrate the benefits of collaborating to advance the science of transplantation and connecting breakthroughs to patients this week at the 48th Annual Meeting of the American Society for Histocompatibility & Immunogenetics (ASHI) Conference in Las Vegas. The innovations will be featured in a number of abstracts, three sponsored sessions and the launch of a new patient advocacy campaign, which can be seen at booth #100.

Among the innovations to be showcased by Thermo Fisher’s transplant diagnostics business are two separate multi-center studies at European, South American, Asian and United States transplant centers that were conducted to evaluate the One Lambda AllType FASTplex assay—a unique and easy-to-use next-generation sequencing assay for human leukocyte antigen (HLA) typing—in clinical settings. High-resolution genotyping of the HLA locus is key to ensuring the best donor–recipient match. The studies demonstrated robust performance and accurate typing results.

The leading maker of transplant diagnostics will also debut its Counting on you patient advocacy campaign, which celebrates the lives of transplant recipients by “counting” their extraordinary and everyday milestones post-transplant. The campaign also gives the recipients a platform to say thank you to their donors and the individuals whose work enables the lifesaving miracle of transplantation. The campaign represents the evolution of the company’s transplant patient advocacy efforts. Earlier this year, One Lambda, a Thermo Fisher Scientific brand, sponsored the Letters of Hope docuseries, which recently won an award for positive storylines related to organ transplantation.

“The work being done in transplant laboratories around the globe is the reason we are able to move the science of transplantation forward,” said Nicole Brockway, president, transplant diagnostics, Thermo Fisher Scientific. “We’re proud to partner with our customers to deliver the workflow of the future to help improve the quality of life for transplant recipients. As our new patient advocacy campaign vividly affirms, transplant recipients make the world a better place simply by being a part of it.”

Other One Lambda–branded technologies to be highlighted at the conference include TypeStream Visual NGS Analysis Software (TSV) and a unique, highly efficient, rapid, and accurate method for typing noncoding sequences that have been shown to be important to transplant patient outcomes.

See Letters of Hope and the Counting on you stories at onelambda.com/patient-advocacy

Sponsored sessions

Pre-ASHI Workshop
Monday, October 24, 2022
1:00–4:00 p.m. PT
Palace Meeting Room #3

User Group Meeting: Increasing Confidence in Your Virtual Crossmatching
Tuesday, October 25, 2022
12:15–2:05 p.m. PT
Jubilee Tower (Jubilee 1)

User Group Meeting: Evolving Perspectives on Epitopes: Debating the Emerging Research
Wednesday, October 26, 2022
11:45–1:35 p.m. PT
Jubilee Tower (Jubilee 1)

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Deborah Bright
Phone: 760-271-4239
E-mail: deborah.bright@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Deborah Bright
Phone: 760-271-4239
E-mail: deborah.bright@thermofisher.com

More News From Thermo Fisher

Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle

ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sacrificing the simplicity, durability, and approachable price points they expect from a Nalgene bottle. The result is a slim 24-oz bottle paired with a new interchangeable Fresh Flow cap that lets fans sip from a straw, chug from a spout, or swap the cap onto other Nalgene bottles they already own. T...

Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum. The recognition highlights the strength of Thermo Fisher’s PPD™ clinical research business, which is recognized for its capabilities in clinic...

Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to s...
Back to Newsroom